CXCL8 and renal cell carcinoma: Specifically, the chemokine IL8 has been shown to underpin the angiogenic response of HIF-1α–deficient/VEGF-depleted DLD-1 colon cancer xenografts (31), and mediate the resistance of head and neck squamous cell carcinoma and renal cell carcinoma to Bevacizumab (32) and Sunitinib (33), respectively.